This newsletter presents you the following key sessions:
1. Video with Prof. Patrick Neven about long-term follow-up data of MONARCHE confirm adjuvant abemaciclib
plus endocrine therapy as standard of care for patients with high-risk, HR+/HER2- early breast cancer
2. Perioperative nivolumab combined with neoadjuvant chemotherapy significantly improves the event-free
survival of patients with resectable non-small cell lung cancer
3. Adjuvant alectinib significantly improves the disease-free survival of patients with early-stage non-small
cell lung cancer harbouring ALK rearrangements
4. Induction chemotherapy prior to chemoradiotherapy improves the survival of patients with locally
advanced cervical cancer
5. Senaparib maintenance significantly delays disease progression in patients with advanced ovarian cancer